FREDERICK, Md., Aug. 26, 2014 /PRNewswire/ -- BioElectronics
Corporation (OTC Pink: BIEL), the maker of advanced drug-free
consumer medical devices, today released the updated results of its
"Try It and Tell Us" 7-day ActiPatch sample program for
United Kingdom and Ireland residents who were surveyed about
their experience. Overall results for
chronic musculoskeletal pain showed a 77%
efficacy to ActiPatch Therapy with an average pain decrease of 52%.
Visit www.bielcorp.com/clinical-evidence/musculoskeletal-pain to
see the 430 consumer responses and www.facebook.com/ActiPatch to
view what people in the UK and Ireland are saying about the products.
"These consistent results across varied disease states establish
two critical facts," said Ian Rawe,
Ph.D., Director of Clinical Research at BioElectronics
Corporation. "ActiPatch Therapy works on the fundamental
problem of inflammation and pain and it is meeting a critical unmet
need in chronic pain management."
Specific disease condition results were:
- Chronic Back Pain sufferers reported 76% efficacy to
ActiPatch Therapy with a 50% improvement in average pain
levels.
- Osteoarthritis sufferers have a higher baseline pain
average and 85% of them reported efficacy to ActiPatch Therapy with
a pain level drop of 52%
- Fibromyalgia sufferers; 75% efficacy to ActiPatch
Therapy with a 49 % decrease in pain.
- Rheumatoid Arthritis sufferers; reported 83% efficacy to
ActiPatch Therapy with a 52% average drop in pain.
- Post-Surgery Chronic Pain sufferers; 66% efficacy to
ActiPatch, Therapy with a 52% decrease in pain.
- Neuropathy sufferers; 64% efficacy to ActiPatch, Therapy
with a 51% decrease in pain.
ActiPatch Therapy devices are readily available over-the-counter
outside of the US, for approximately $30.00, retail or $0.04 per hour of therapy.
BioElectronics Executive Vice President, Deepak Kotak, M.D. a Fellow of the Royal College
of Anesthesiology observed that the American Pain Foundation 2006
patient survey, Voices of Chronic Pain revealed that
half of chronic pain patients taking opioid analgesics felt they
had little or no control of their pain.
"With chronic pain affecting approximately 50 million Americans,
this lack of control represents a major public health concern and
indicates much chronic pain may be untreated, undertreated or
improperly treated." Dr. Kotak concluded, "This ActiPatch UK
consumer survey shows that even with better understanding of
chronic pain and more drugs available, chronic pain sufferers still
have unacceptably high baseline pain levels underscoring the urgent
need for new efficacious pain therapies such as ActiPatch that can
be self administered to reduce or obviate the need for prescription
drugs, particularly opiates."
About BioElectronics Corporation
BioElectronics
Corporation is a leader in Bioelectronics and the maker of a family
of disposable, drug-free, medical devices: ActiPatch®
Therapy, over-the-counter treatment for back pain and other
musculoskeletal complaints; RecoveryRx® Devices for
chronic and post-operative wound care; Allay® Menstrual
Pain Therapy; and HealFast® Therapy for dogs, cats and
horses. For more information, please visit
www.bielcorp.com.
Contact: Paul Knopick:
940.262.3584
pknopick@eandecommunications.com
SOURCE BioElectronics Corporation